The convergence of life sciences and technology has created tremendous opportunities to accelerate innovation in the industry. This acceleration was further fueled by the COVID-19 pandemic, where the race to develop new therapies and vaccines to treat COVID-19 resulted in an unprecedented number of transactions between and among companies of all shapes and sizes, including competitors.
This roundtable discussion, led by Matt Karlyn and Mai Zymaris of Morrison & Foerster’s Boston Life Sciences Group, will focus on best practices and considerations for any company entering into a collaboration or licensing deal. Topics include:
- Best practices and pitfalls of negotiating term sheets, including level of detail, exclusivity, binding provisions
- Deal structures, including cost-sharing, co-promotion, options, territory deals, pricing structures, exclusivity, termination provisions/fees, and equity investments
- Additional complexities for new modalities such as ADCs, bi-specifics, and combination therapies
- Increased antitrust scrutiny and considerations for drafting
- Case studies in collaboration, covering lessons learned, and what general counsel need to know in today’s market